dc.creatorRath S.
dc.creatorAugusto Trivelin L.
dc.creatorImbrunito T.R.
dc.creatorTomazela D.M.
dc.creatorDe Jesus M.N.
dc.creatorCalvo Marzal P.
dc.creatorDe Andrade Jr. H.F.
dc.creatorGustavo Tempone A.
dc.date2003
dc.date2015-06-30T17:27:57Z
dc.date2015-11-26T15:39:53Z
dc.date2015-06-30T17:27:57Z
dc.date2015-11-26T15:39:53Z
dc.date.accessioned2018-03-28T22:48:20Z
dc.date.available2018-03-28T22:48:20Z
dc.identifier
dc.identifierQuimica Nova. , v. 26, n. 4, p. 550 - 555, 2003.
dc.identifier1004042
dc.identifier
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-0742304906&partnerID=40&md5=7025fcc13153131dc1b8d5a062a07809
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/102103
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/102103
dc.identifier2-s2.0-0742304906
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1264237
dc.descriptionAntimony preparations are the drugs of choice for the treatment of leishmaniasis over 90 years, a disease that currently affects 12 million people worldwide. Its introduction was based on 19th century concepts of therapeutic effects of metal salts as arsenicals and other metals, most of them abandoned due to toxic effects or better drugs. In the last three decades, there was a great improvement in the knowledge of cell biology and immunology of those infections, but chemotherapy has not been improved in the same strength. The structure and mechanism of action of the two pentavalent antimonial drugs of choice, meglumine antimoniate and sodium stibogluconate, are not well known and the contamination of those pharmaceutical by toxic contaminants have been verified.
dc.description26
dc.description4
dc.description550
dc.description555
dc.descriptionGoldman, L., (1983) Arch. Dermatol., 119, p. 540
dc.descriptionhttp://www.dbbm.fiocruz.br/tropical/leishman/indice.htmlHoare, C.A., (1938) Trans. R. Soc. Trop. Med. Hyg., 32, p. 67
dc.descriptionhttp://www.sucen.sp.gov.br/doencas/index.htmBerman, J.D., (1988) Rev. Infect. Dis., 10, p. 560
dc.descriptionhttp://www.funasa.gov.br/pub/GVE/GVE0517A.htmGrimaldi, G., Tesh, A.B., McMahon, P.D., (1989) Am. J. Trop. Med. Hyg., 41, p. 689
dc.descriptionhttp://www.who.int/emc/diseases/leish/leisgeol.htmlZorzetto, R., (2001) Pesquisa FAPESP, 68, p. 53
dc.descriptionhttp://www.cve.saude.sp.gov.br/htm/leishvis.htmhttp://www.cve.saude.sp.gov.br/htm/inf_lva2000.htmVianna, G.O., (1912) Anais do 7° Congresso Brasileiro de Medicina e Cirurgia, 4, p. 426
dc.descriptionDi Christina, G., Caronia, G., (1915) Bull. Soc. Pathol. Exot., 8, p. 63
dc.descriptionMarsden, P.D., (1985) Rev. Soc. Bras. Med. Trop., 18, p. 187
dc.descriptionMoore, E., O'Flaherty, D., Heuvelmans, H., Seaman, J., Veeken, H., Wit, S., Davidson, R.N., (2001) Bulletin of the World Health Organization, 79, p. 388
dc.descriptionLimongi, J.P., (1973) Farmacodinâmica, , Corbett, C. E., ed.
dc.descriptionLivraria Editera Artes Médicas: São Paulo, cap. 61
dc.descriptionGoldsmith, R.S., (1998) Farmacologia Básica e Clínica, , Katzung, B. G., ed.
dc.descriptionGuanabara Koogan S.A.: Rio de Janeiro, cap. 54
dc.descriptionBalaña-Fouce, R., Reguera, R.M., Cubría, C., Ordóñez, D., (1998) Gen. Pharmacol., 30, p. 435
dc.descriptionSereno, D., Lemesre, J.L., (1997) Antimicrob. Agents Chemother., 41, p. 972
dc.descriptionBerman, J.D., Wyler, D.J., (1980) J. Inf. Diseases, 142, p. 83
dc.descriptionRoberts, W.L., McMurray, W.J., Rainey, P.M., (1998) Antimicrob. Agents Chemother., 42, p. 1076
dc.descriptionDórea, J.G., Costa, J.M.L., Holzbecher, J., Ryan, D.E., Marsden, P.D., (1987) Clin. Chem., 33, p. 2081
dc.descriptionDemicheli, C., Figueiredo, T.L., Carvalho, S., Sinesterra, R.D., Lopes, J.C.D., Frezard, F., (1999) BioMetals, 12, p. 63
dc.descriptionBangs, J.D., Ransom, D.A., Nimick, M., Christie, G.H., (2001) Mol. Biochem. Parasitol., 114, p. 111
dc.descriptionMiekeley, N., Mortari, S.R., Schubach, A.O., (2002) Anal. Bioanal. Chem., 372, p. 495
dc.descriptionDoua, F., Miezan, T.W., Singaro, J.R.S., Yapo, F.B., Baltz, T., (1996) Am. J. Trop. Med. Hyg., 55, p. 586
dc.descriptionYardley, V., Croft, S.L., (2000) Int. J. Antimicrob. Agents, 13, p. 243
dc.descriptionRang, H.P., Dale, M.M., (1991) Pharmacology
dc.description2nd Ed., , Churchill Livingstone: UK
dc.descriptionMartinez, S., Marr, J.J., (1992) New Engl. J. Med., 326, p. 741
dc.descriptionFischer, C., Voss, A., Engel, J., (2001) Medical Microbiol. Immunolog., 190, p. 85
dc.descriptionhttp://www-cie.iarc.fr/htdocs/monographs/vol47/47-11.htmGerhardsson, L., Brune, D., Nordberg, G.F., Wester, P.O., (1982) Scand. J. Work Environ. Health, 8, p. 201
dc.descriptionJones, R.D., (1994) Occup. Environ. Med., 51, p. 772
dc.descriptionGroth, D.H., Stettler, L.E., Burg, J.R., Busey, W.M., Grant, G.C., Wong, L., (1986) J. Toxicol. Environ. Health, 18, p. 607
dc.descriptionGebel, T., (1997) Chem.-Biol. Interact., 107, p. 131
dc.descriptionFelicetti, S.A., Thomas, R.G., McClellan, R.O., (1974) Am. Ind. Hyg. Assoc. J., 35, p. 292
dc.descriptionChulay, J.D., Fleckenstein, L., Smith, D.H., (1988) Trans. R. Soc. Trop. Med. Hyg., 82, p. 69
dc.descriptionRees, P.H., Kesting, M.I., Kager, P.A., Hockmeyer, W.T., (1980) Lancet, 2, p. 226
dc.descriptionPamplin, C.L., Desjadins, R., Chulay, J., Tramont, E., Henricks, L., Canfield, C., (1981) Clin. Pharm. Ther., 29, p. 270
dc.descriptionKrachler, M., Emons, H., (2001) J. Anal. At. Spectrom., 16, p. 20
dc.descriptionBloomfield, M.S., Dow, D.A., Prebble, K.A., (1992) J. Pharm. Biomed. Anal., 10, p. 779
dc.descriptionFranco, A., Barbosa, A.C., Rath, S., Dórea, J.G., (1995) Am. J. Trop. Med. Hyg., 52, p. 435
dc.descriptionRath, S., Jardim, W.F., Dórea, J.G., (1997) Fresenius' J. Anal. Chem., 358, p. 548
dc.descriptionhttp://www.ufsm.br/farmacopeia/.html
dc.languagept
dc.publisher
dc.relationQuimica Nova
dc.rightsaberto
dc.sourceScopus
dc.titleAntimonials Employed In The Treatment Of Leishmaniaisis: The State Of The Art [antimoniais Empregados No Tratamento Da Leishmaniose: Estado Da Arte]
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución